After successfully demonstrating that DTX treatment can upregulate the expression of PD-L1 on tumor cells and thereby promote the uptake of αPD-L1, which is expected to improve the immunotherapeutic efficacy of PD-L1, we evaluated the ability of the RD@MBs system to activate the immune response in vitro. This evidence concerns the gene CD274 and neoplasm.